Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2026-014803 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Rikke Løvendahl Eefsen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Herlev Hospital, Herlev, Capital Region of Denmark, Denmark rikke.helene.loevendahl.eefsen@regionh.dk. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ipilimumab, Nivolumab, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Varian, Danish Comprehensive Cancer Center -Immuno-Radiotherapy Group, Danish Comprehensive Cancer Center - Immunotherapy Group.
Abstract (Originalsprache)
Background
Metastatic castration-resistant prostate cancer (mCRPC) is among the leading causes of cancer-related mortality in men worldwide. Treatment options for mCRPC typically include chemotherapy and androgen receptor pathway inhibitors. Immune checkpoint inhibitors (ICIs) have demonstrated a limited effect in mCRPC. We hypothesized that the addition of stereotactic body radiation therapy (SBRT) could enhance immune responses and improve treatment outcomes.
Methods
Patients with mCRPC who had received at least two prior lines of therapy were randomized 1:1 to receive SBRT with nivolumab and ipilimumab (arm A) or nivolumab and ipilimumab (arm B). The dual primary endpoints in the study were prostate-specific antigen (PSA) response rate and objective response rate (ORR). Secondary endpoints included overall survival (OS), PSA, radiologic progression-free survival, and toxicity.
Results
We enrolled 91 patients, and 81 patients received at least one treatment with ICIs and were eligible for evaluation of the efficacy and safety endpoints. Of the evaluable patient population, the confirmed PSA response rate was 21.6% (95% CI 9.8% to 38.2%) in arm A, and 20.5% (95% CI 9.8% to 35.3%) in arm B. ORR was 16.7% (95% CI 4.7% to 37.4%) and 22.2% (95% CI 10.1% to 39.2%) in arms A and B, respectively. Median OS was 10.2 months (95% CI 7.1 to 15.2) in arm A and 9.2 months (95% CI 7.1 to 14.4) in arm B. Treatment-related adverse events grade 3–4 were observed in 27 patients (33.3%).
Conclusions
The addition of SBRT to nivolumab and ipilimumab did not improve outcomes; however, a fraction of the patients had a response to the treatment combination of nivolumab and ipilimumab. Explorative translational research is needed to identify possible biomarkers of response to immunotherapy with ICIs in mCRPC. Trial registration numbers European Union Clinical Trial Registry ( https://www.clinicaltrialsregister.eu ) EudraCT number: 2018-003461-34 and on https://clinicaltrials.gov ( NCT05655715 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Herlev Hospital, Herlev, Capital Region of Denmark, Denmark rikke.helene.loevendahl.eefsen@regionh.dk.
- Department of Oncology, Herlev Hospital, Herlev, Capital Region of Denmark, Denmark.
- Department of Radiology, Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark.
- Department of Nuclear Medicine, Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark.
- Department of Surgery, Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark.
- University of Copenhagen, Copenhagen, Denmark.
Förderung
- Varian
- Danish Comprehensive Cancer Center -Immuno-Radiotherapy Group
- Danish Comprehensive Cancer Center - Immunotherapy Group
- Bristol Myers Squibb Foundation
- Neye
Zitieren
APA
Eefsen, R. L., Spindler, N. J., Theile, S., Al-Farra, G., Hendel, H. W., Lorentzen, T., Fredberg Persson, G., Behrens, C. P., Chen, I. M., Madsen, K., Sengeløv, L., Svane, I. M., Lindberg, H., Kongsted, P., & Nielsen, D. L. (2026). Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-014803
Vancouver
Eefsen RL, Spindler NJ, Theile S, Al-Farra G, Hendel HW, Lorentzen T, et al. Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-014803
BibTeX
@article{Eefsen2026,
author = {Eefsen, Rikke Løvendahl and Spindler, Nicklas Juel and Theile, Susann and Al-Farra, Gina and Hendel, Helle W and Lorentzen, Torben and Fredberg Persson, Gitte and Behrens, Claus P and Chen, Inna Markova and Madsen, Kasper and Sengeløv, Lisa and Svane, Inge Marie and Lindberg, Henriette and Kongsted, Per and Nielsen, Dorte Lisbeth},
title = {Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2026-014803}
}
EUVIMED